Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non Operating Income (2018 - 2025)

Historic Non Operating Income for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $3.2 million.

  • Arcturus Therapeutics Holdings' Non Operating Income fell 1529.6% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year decrease of 3751.79%. This contributed to the annual value of $15.2 million for FY2024, which is 841.42% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Non Operating Income stood at $3.2 million, which was down 1529.6% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Non Operating Income ranged from a high of $6.9 million in Q4 2023 and a low of -$564000.0 during Q1 2022
  • Its 5-year average for Non Operating Income is $2.0 million, with a median of $2.6 million in 2025.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Non Operating Income crashed by 228181.82% in 2021, and later soared by 134018.69% in 2023.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Non Operating Income (Quarter) stood at -$524000.0 in 2021, then skyrocketed by 295.61% to $1.0 million in 2022, then surged by 571.32% to $6.9 million in 2023, then tumbled by 53.29% to $3.2 million in 2024, then rose by 0.62% to $3.2 million in 2025.
  • Its Non Operating Income was $3.2 million in Q3 2025, compared to $2.6 million in Q2 2025 and $2.8 million in Q1 2025.